Skip to main content

Table 2 Group comparison of EEG characteristics and NBM volume

From: EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease

 HCADLBDGroup comparison
Individual alpha peak8.8 [8.4, 9.2]7.4 [6.3, 8.4]6.4 [6.1, 6.7]F2 = 42.1, p < 0.001a
p (HC, AD) = 0.004
p (HC, LBD) < 0.001
p (AD, LBD) = 0.092
Alpha reactivity0.56 [0.50, 0.63]0.24 [0.12, 0.34]0.08 [0.03, 0.14]F2 = 59.9, p < 0.001b
p (HC, AD) < 0.001
p (HC, LBD) < 0.001
p (AD, LBD) = 0.014
Eyes-closed alpha power49.1 [41.9, 56.3]34.4 [27.5, 41.3]39.7 [35.8, 43.5]F2 = 7.9, p = 0.019a
p (HC, AD) = 0.018
p (HC, LBD) = 0.25
p (AD, LBD) = 0.56
Eyes-open alpha power18.9 [16.1, 21.7]24.2 [19.4, 29.0]36.7 [32.4, 41.1]F2 = 35.5, p < 0.001a
p (HC, AD) = 0.25
p (HC, LBD) < 0.001
p (AD, LBD) = 0.005
NBM volume0.19 [0.18, 0.20]0.17 [0.16, 0.17]0.16 [0.15, 0.17]F2 = 13.3, p < 0.001b
p (HC, AD) = 0.003
p (HC, LBD) < 0.001
p (AD, LBD) = 1.0
  1. Mean [95% confidence interval]. Alpha power and alpha reactivity estimated from electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM volume normalised to total intracranial volume. Group differences assessed by univariate ANOVA or Kruskal-Wallis ANOVA with post hoc tests corrected for multiple comparisons
  2. AD Alzheimer’s disease, HC healthy controls, LBD Lewy body dementia, NBM nucleus basalis of Meynert
  3. aKruskal-Wallis ANOVA
  4. bUnivariate ANOVA